A randomized, open label, single dose, crossover, bioequivalence study of Prazosin 5mg tablet produced by Amin Pharm Co., IRAN in comparison owith MiniPress 5mg tablet produced by Laphal Co. in 24 healthy adult subjects under fasting condition

Amin Pharm. Co.0 个研究点目标入组 24 人开始时间: 待定最近更新: 2022年2月7日

试验速览

暂无简介。

•Aged between 18 - 50 years
•Body weight between 50 – 100 kg
•Having good health on the basis of medical history and physical & clinical examination
•Understand the procedures and give written informed consent

•History of the gastro-intestinal tract surgery
•Subject with a history of blood donation or participation in another clinical trial, within the last two months before the first treatment
•Subject with a history of drug or alcohol abuse.
•Subject who smokes more than 10 cigarettes per day.
•Subject with a history of disease leading to using drug within 14 days, or any non-prescription medication within 7 days, before the first treatment.

发起方

Amin Pharm. Co.